Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9325
Title: Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Austin Authors: Cao, Zemin;Burrell, Louise M ;Tikkanen, Ilkka;Bonnet, Fabrice;Cooper, Mark E;Gilbert, Richard E
Affiliation: University of Melbourne Department of Medicine at Austin and Repatriation Medical Centre, Heidelberg West, Victoria, Australia
Issue Date: 1-Aug-2001
Publication information: Kidney International; 60(2): 715-21
Abstract: Vasopeptidase inhibitors are a new class of cardiovascular compounds that inhibit both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). The aim of the present study was to explore the effects of omapatrilat, a vasopeptidase inhibitor, on renal function and pathology in subtotally nephrectomized (STNx) rats.STNx rats were randomized to four groups and treated for 12 weeks: no treatment (N = 14); omapatrilat at a low dose of 10 mg/kg (L, N = 12) and at a high dose of 40 mg/kg (H, N = 10); or an ACE inhibitor, fosinopril, at a dose of 10 mg/kg (N = 12). Sham-operated rats were used as control animals (N = 12).Elevated blood pressure in STNx rats (174 +/- 9 mm Hg) was reduced by omapatrilat in a dose-dependent manner (L, 121 +/- 3 mm Hg; H, 110 +/- 3 mm Hg) and by fosinopril (149 +/- 5 mm Hg). Proteinuria in STNx rats (246 +/- 73 mg/day) was reduced by treatment with fosinopril (88 +/- 21 mg/day) and was normalized by treatment with omapatrilat (L, 30 +/- 4 mg/day; H, 20 +/- 2 mg/day vs. control 25 +/- 1 mg/day). Decreased glomerular filtration rates, elevated plasma urea and creatinine and glomerulosclerosis, and tubulointerstitial fibrosis were ameliorated by omapatrilat and fosinopril to a similar degree. Compared with fosinopril, omapatrilat treatment was associated with increased plasma renin activity and decreased renal ACE and NEP binding in a dose-dependent manner.These findings suggest that vasopeptidase inhibition may provide a useful strategy for the treatment of progressive renal disease.
Gov't Doc #: 11473654
URI: https://ahro.austin.org.au/austinjspui/handle/1/9325
DOI: 10.1046/j.1523-1755.2001.060002715.x
Journal: Kidney International
URL: https://pubmed.ncbi.nlm.nih.gov/11473654
Type: Journal Article
Subjects: Angiotensin-Converting Enzyme Inhibitors.pharmacology
Animals
Autoradiography
Blood Pressure.drug effects
Creatinine.blood
Disease Models, Animal
Fosinopril.pharmacology
Glomerular Filtration Rate
Heart Failure.drug therapy.metabolism
Hypertension, Renal.drug therapy.metabolism.pathology
Kidney.enzymology
Male
Nephrectomy
Neprilysin.analysis.antagonists & inhibitors.metabolism
Organ Size
Peptidyl-Dipeptidase A.analysis.metabolism
Proteinuria.drug therapy.pathology
Pyridines.pharmacology
Rats
Rats, Sprague-Dawley
Renal Insufficiency.drug therapy.metabolism.pathology
Renin.blood
Thiazepines.pharmacology
Urea.blood
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.